RESUMEN
PURPOSE: In patients receiving non-intubated video-assisted thoracic surgery (NIVATS), transnasal humidified rapid-insufflation ventilatory exchange (THRIVE) has been applied instead of oxygen mask for better oxygenation. However, the THRIVE effects on intraoperative temperature decrease have not been investigated. METHODS: Pre- and postoperative temperatures, measured by an infrared tympanic ear thermometer, taken before sending patients to the operation room and immediately upon their arrival in the postoperative anesthesia unit, were collected from medical records of patients who received NIVATS either with oxygen mask or THRIVE. Intraoperative temperature decrease, calculated by preoperative temperature minus postoperative temperature, was compared between different groups. Multiple linear regression analysis was performed to determine factors associated with intraoperative temperature decrease. RESULTS: Records of 256 adult patients with forced-air warming were retrospectively analyzed. 172 patients of them received THRIVE and 84 patients received oxygen mask. Preoperative temperatures were comparable between groups (THRIVE: 36.25 ± 0.46 °C; mask: 36.30 ± 0.39 °C, p = 0.43). Postoperative temperatures were significantly higher in patients using THRIVE than those using oxygen masks (36.05 ± 0.59 vs 35.87 ± 0.62 °C, p = 0.025). Significantly less intraoperative temperature decrease was shown in THRIVE group (THRIVE: 0.20 ± 0.69 °C; mask: 0.43 ± 0.69 °C, p = 0.04). According to the multiple linear regression analysis, significant temperature decrease was associated with the advanced age (ßage = 0.01) but not the anesthetic duration. Using THRIVE was correlated with significantly less body temperature decrease (ßTRIVE = - 0.24). CONCLUSIONS: THRIVE effectively prevents intraoperative temperature decrease during NIVATS, especially in old patients.
Asunto(s)
Temperatura Corporal , Hipotermia/prevención & control , Terapia por Inhalación de Oxígeno/métodos , Cirugía Torácica Asistida por Video/métodos , Anciano , Estudios de Cohortes , Femenino , Calor , Humanos , Insuflación , Masculino , Máscaras , Persona de Mediana Edad , Oxígeno/administración & dosificación , Periodo Posoperatorio , Estudios Retrospectivos , TemperaturaRESUMEN
The biliprotein phytochrome regulates plant growth and developmental responses to the ambient light environment through an unknown mechanism. Biochemical analyses demonstrate that phytochrome is an ancient molecule that evolved from a more compact light sensor in cyanobacteria. The cyanobacterial phytochrome Cph1 is a light-regulated histidine kinase that mediates red, far-red reversible phosphorylation of a small response regulator, Rcp1 (response regulator for cyanobacterial phytochrome), encoded by the adjacent gene, thus implicating protein phosphorylation-dephosphorylation in the initial step of light signal transduction by phytochrome.
Asunto(s)
Proteínas Bacterianas , Cianobacterias/metabolismo , Luz , Proteínas Quinasas/metabolismo , Secuencia de Aminoácidos , Clonación Molecular , Cianobacterias/química , Cianobacterias/genética , Genes Bacterianos , Histidina Quinasa , Datos de Secuencia Molecular , Operón , Fosforilación , Proteínas Quinasas/química , Proteínas Quinasas/genética , Proteínas , Proteínas Recombinantes de Fusión/química , Proteínas Recombinantes de Fusión/metabolismo , Eliminación de Secuencia , Transducción de SeñalRESUMEN
Plants constantly monitor their light environment in order to grow and develop optimally, in part through use of the phytochromes, which sense red/far-red light. A phytochrome binding protein, PKS1 (phytochrome kinase substrate 1), was identified that is a substrate for light-regulated phytochrome kinase activity in vitro. In vivo experiments suggest that PKS1 is phosphorylated in a phytochrome-dependent manner and negatively regulates phytochrome signaling. The data suggest that phytochromes signal by serine-threonine phosphorylation.
Asunto(s)
Proteínas de Arabidopsis , Arabidopsis/metabolismo , Proteínas Portadoras/metabolismo , Péptidos y Proteínas de Señalización Intracelular , Luz , Fosfoproteínas/metabolismo , Células Fotorreceptoras , Fitocromo/metabolismo , Proteínas de Plantas , Transducción de Señal , Factores de Transcripción , Secuencia de Aminoácidos , Arabidopsis/genética , Proteínas Portadoras/química , Proteínas Portadoras/genética , Genes de Plantas , Histidina Quinasa , Proteínas de la Membrana , Datos de Secuencia Molecular , Mutación , Fosfoproteínas/química , Fosfoproteínas/genética , Fosforilación , Fitocromo A , Fitocromo B , Proteínas Quinasas/metabolismo , Proteínas Serina-Treonina Quinasas/metabolismo , Proteínas Recombinantes de Fusión/metabolismoRESUMEN
BACKGROUND/AIMS: In the present study, we attempted to develop a simulated model to explore the causal effects of periodontal pathogens on skeletal homeostasis in postmenopausal osteoporosis. METHODS: Fifty-three female adult ICR mice were randomly assigned to an experimental group (ovariectomized) or a control group. A single injection of Porphyromonas gingivalis lipopolysaccharide (P. gingivalis-LPS, ATCC 33277) or Escherichia coli lipopolysaccharide (E. coli-LPS) was administered intraperitoneally 4 weeks after an ovariectomy. Concentrations of interleukin-6 (IL-6), osteoprotegerin (OPG), and the receptor activator of nuclear factor-kappaB ligand (RANKL) in serum were subsequently analyzed using an enzyme-linked immunosorbent assay (ELISA). RESULTS: Under stimulation with P. gingivalis-LPS or E. coli-LPS, the concentration of OPG rose in both groups. The serum level of RANKL showed a decreasing trend 24 h after the injection in both groups. After injection of P. gingivalis-LPS in both the experimental and control animals, the OPG : RANKL ratio increased 24 h after the booster (22.26-620.99, P < 0.05). The serum level of IL-6 in the experimental group significantly increased 1-6 h after administration of E. coli-LPS and 1-3 h after administration of P. gingivalis-LPS (P < 0.05). CONCLUSIONS: A single booster injection of P. gingivalis-LPS induced short-term changes in OPG, RANKL, and IL-6 serum levels in this ovariectomized mouse model.
Asunto(s)
Interleucina-6/sangre , Lipopolisacáridos/farmacología , Osteoprotegerina/sangre , Ovariectomía , Porphyromonas gingivalis , Ligando RANK/sangre , Animales , Modelos Animales de Enfermedad , Escherichia coli , Femenino , Homeostasis/efectos de los fármacos , Homeostasis/fisiología , Inyecciones Intraperitoneales , Lipopolisacáridos/administración & dosificación , Ratones , Ratones Endogámicos ICR , Osteoporosis/fisiopatología , Osteoprotegerina/efectos de los fármacos , Ligando RANK/efectos de los fármacos , Distribución Aleatoria , Factores de TiempoRESUMEN
Bioavailabilities of dexamethasone tablets and elixir in man were evaluated by each of 3 model-independent methods of pharmacokinetic analysis employing plasma and urinary values as determined by radioimmune assay. There were no significant differences among the results determined by the 3 methods nor between the respective availabilities of the two formulations; the latter averaged 82.6 +/- 17.7% for the elixir formulation and 78.0 +/- 12.1% for tablets.
Asunto(s)
Dexametasona/metabolismo , Administración Oral , Adolescente , Adulto , Disponibilidad Biológica , Ensayos Clínicos como Asunto , Dexametasona/administración & dosificación , Humanos , Infusiones Parenterales , Cinética , Masculino , Soluciones , Comprimidos , Factores de TiempoRESUMEN
Plasma levels of dexamethasone phosphate (DP) and dexamethasone free alcohol (DA) were determined by a modification of existing radioimmunoassay methodology following intravenous administration of DP in man. Areas under DA plasma profiles were a linear function of DP dosage over the 40-fold range 0.05 to 2.0 mg/kg, and, by comparison with values obtained after DA was intravenously administered, indicated an overall conversion of DP to DA of 90%. The first-order rate constant for the conversion, 4.03 hr-1, was approximately 25 times that for hydrolysis in whole blood incubated in vitro. This relationship as well as disposition kinetics suggested that the major component of DP hydrolysis occurs within highly perfused organ(s) comprising the central kinetic compartment. Eighteen subjects were studied in a crossover experiment, and no significant differences were observed in best-fit parameters for the 4 mg/ml parenteral solution of DP in current use and an experimental high potency preparation of 24 mg/ml.
Asunto(s)
Dexametasona/metabolismo , Adolescente , Adulto , Alcoholes/metabolismo , Disponibilidad Biológica , Ensayos Clínicos como Asunto , Dexametasona/administración & dosificación , Dexametasona/sangre , Femenino , Semivida , Humanos , Hidrólisis , Infusiones Parenterales , Inyecciones Intravenosas , Masculino , Modelos Biológicos , Fosfatos/metabolismo , Relación Estructura-ActividadRESUMEN
Diflunisal is long-acting salicylate derivative. We examined the effect of single concomitant doses of three antacids on diflunisal bioavailability under fasting or fed conditions (30 min after finishing a standard meal). With the use of an open, randomized, and balanced design, one 250-mg diflunisal tablet was given to each of 12 healthy men under six conditions: fasted, no antacid; fed, no antacid; fasted, 15 ml of aluminum hydroxide gel; fed, 15 ml of aluminum hydroxide gel; fasted, 10 ml magnesium hydroxide suspension; and fed, 15 ml of an aluminum hydroxide/magnesium hydroxide mixture. Diflunisal plasma 0- to 48-hr area uiven to each of 12 healthy men under six conditions: fasted, no antacid; fed, no antacid; fasted, 15 ml of aluminum hydroxide gel; fed, 15 ml of aluminum hydroxide gel; fasted, 10 ml magnesium hydroxide suspension; and fed, 15 ml of an aluminum hydroxide/magnesium hydroxide mixture. Diflunisal plasma 0- to 48-hr area uiven to each of 12 healthy men under six conditions: fasted, no antacid; fed, no antacid; fasted, 15 ml of aluminum hydroxide gel; fed, 15 ml of aluminum hydroxide gel; fasted, 10 ml magnesium hydroxide suspension; and fed, 15 ml of an aluminum hydroxide/magnesium hydroxide mixture. Diflunisal plasma 0- to 48-hr area under the time curve (AUC), peak plasma concentrations, and 0-to 96-hr urinary excretion were determined. Food (alone) decreased peak plasma concentrations by 16% (P less than 0.05) but did not affect AUC or urinary excretion. Under fasting conditions, aluminum hydroxide reduced AUC by 26% (P less than 0.01), peak plasma concentrations by 46% (P less than 0.01), and urinary excretion by 14% (P less than 0.05). Magenisuum hydroxide suspension (in the fasting state) increased the early plasma concentrations (by 130% at 0.5 hr and 64% at 1 hr, P less than 0.05) and increased AUC by 10% (P less than 0.05) but had no effect on urinary excretion. In the fed state neither aluminum hydroxide nor the aluminum hydroxide/magnesium hydroxide mixture had any detectable effect.
Asunto(s)
Antiácidos/farmacología , Diflunisal/metabolismo , Salicilatos/metabolismo , Adulto , Hidróxido de Aluminio/metabolismo , Disponibilidad Biológica , Ensayos Clínicos como Asunto , Diflunisal/sangre , Diflunisal/orina , Ayuno , Alimentos , Geles , Humanos , Hidróxido de Magnesio/metabolismo , Masculino , Suspensiones , Factores de TiempoRESUMEN
Many different formulation techniques are available for designing controlled-release dosage forms. Five different erosion-controlled or diffusion-controlled delivery systems were evaluated to select the 1 most suitable for Sinemet CR. The system ultimately selected, containing carbidopa-levodopa 50-200 mg, is a monolithic matrix tablet designed to have both of its active components released by surface dissolution and erosion. This system was found to be the most effective following extensive in vitro testing, pharmacokinetic studies, and clinical trials. Sinemet CR releases both carbidopa and levodopa by a 1st-order release rate. Controlled-release dosage forms of levodopa with slower in vitro release rates have lower plasma levels.
Asunto(s)
Antiparkinsonianos/administración & dosificación , Carbidopa/administración & dosificación , Levodopa/administración & dosificación , Antiparkinsonianos/farmacocinética , Carbidopa/farmacocinética , Química Farmacéutica , Preparaciones de Acción Retardada , Combinación de Medicamentos/administración & dosificación , Combinación de Medicamentos/farmacocinética , Humanos , Levodopa/farmacocinética , ComprimidosRESUMEN
The pharmacokinetics of Sinemet CR, a controlled-release formulation containing carbidopa and levodopa, were investigated in healthy young and elderly volunteers and in patients with Parkinson's disease. Sinemet CR produced more sustained plasma levels of levodopa, carbidopa, and 3-O methyldopa than did conventional Sinemet. In elderly subjects, the corresponding steady-state plasma levels fluctuated in narrower ranges with Sinemet CR than those following the administration of Sinemet. Results indicate a levodopa bioavailability of 71% for Sinemet CR, in contrast to a bioavailability of 99% for Sinemet for these subjects. The carbidopa bioavailability of Sinemet CR was 58% relative to that of Sinemet. Systemic decarboxylase inhibition was comparable between the 2 regimens as indicated by the renal clearance of levodopa. The absorption of levodopa was slower and more protracted with Sinemet CR than with Sinemet. Food increased the levodopa bioavailability of Sinemet CR. This increase was attributed to an increased gastric retention time. No dose-dumping occurred with Sinemet CR in either the nonfasting or the fasting state. Levodopa bioavailability was lower in young volunteers than in elderly volunteers. This was attributed to an age-related decrease in gastric emptying and in 1st-pass metabolic decarboxylation in the gastrointestinal (GI) tract. In parkinsonian patients, as in healthy subjects, the Sinemet CR formulation produced more sustained levodopa plasma levels. These patients required a higher total daily dosage of Sinemet CR than of Sinemet for control of parkinsonian symptoms, but less frequent dosing was required during chronic therapy. Peak plasma levodopa levels increased proportionately with increasing Sinemet CR dosage. These observations were consistent with the pharmacokinetic characteristics of the formulation.
Asunto(s)
Antiparkinsonianos/farmacocinética , Carbidopa/farmacocinética , Levodopa/farmacocinética , Adolescente , Adulto , Anciano , Antiparkinsonianos/administración & dosificación , Disponibilidad Biológica , Carbidopa/administración & dosificación , Carbidopa/sangre , Ensayos Clínicos como Asunto , Preparaciones de Acción Retardada , Combinación de Medicamentos/administración & dosificación , Combinación de Medicamentos/farmacocinética , Ayuno , Semivida , Humanos , Absorción Intestinal , Levodopa/administración & dosificación , Levodopa/sangre , Persona de Mediana Edad , Enfermedad de Parkinson/sangre , Enfermedad de Parkinson/tratamiento farmacológico , Distribución Aleatoria , Valores de Referencia , Comprimidos , Tirosina/sangreRESUMEN
Indomethacin has a moderately short half-life, usually requiring dosing twice a day or three times a day. A more convenient once or twice daily regimen is made possible with a sustained-release formulation. Following multiple-dose administration of either sustained-release indomethacin (Indocin SR) or conventional indomethacin, drug accumulation is low. Clinical studies indicate comparable safety and efficacy profiles between the two preparations. Pharmacokinetic information on both dosage forms is reviewed.
Asunto(s)
Indometacina/metabolismo , Absorción , Administración Oral , Adulto , Anciano , Antiácidos/farmacología , Disponibilidad Biológica , Ritmo Circadiano , Preparaciones de Acción Retardada , Circulación Enterohepática , Ayuno , Alimentos , Semivida , Humanos , Indometacina/sangre , Cinética , Persona de Mediana Edad , Unión Proteica , Distribución TisularRESUMEN
This study evaluates the safety and potential pharmacokinetic interaction between indinavir and trimethoprim/sulfamethoxazole (TMP/SMZ). In a randomized, three-period crossover fashion, 12 healthy adults received 1 week of indinavir sulfate 400 mg orally every 6 hours with placebo, TMP 160 mg/SMZ 800 mg orally every 12 hours with placebo, and indinavir sulfate with TMP/SMZ. Plasma indinavir, SMZ, and TMP concentrations were determined after the last dose of each treatment period. Concomitant administration resulted in a 17% decrease in geometric mean trough plasma indinavir concentrations (p = 0.032), an 18% increase in geometric mean AUC0-12 h and Cmax TMP values (p = 0.031 and 0.030, respectively), and a 5% increase in geometric mean AUC0-12 h SMZ values (p = 0.039). None of these effects was considered clinically significant. The combination of indinavir sulfate and TMP/SMZ is generally well tolerated, with no clinically significant pharmacokinetic interaction being noted.
Asunto(s)
Antiinfecciosos/farmacocinética , Inhibidores de la Proteasa del VIH/farmacocinética , Indinavir/farmacocinética , Combinación Trimetoprim y Sulfametoxazol/farmacocinética , Dolor Abdominal/inducido químicamente , Administración Oral , Adolescente , Adulto , Antiinfecciosos/efectos adversos , Área Bajo la Curva , Bilirrubina/sangre , Estudios Cruzados , Diarrea/inducido químicamente , Interacciones Farmacológicas , Femenino , Inhibidores de la Proteasa del VIH/efectos adversos , Cefalea/inducido químicamente , Humanos , Indinavir/efectos adversos , Indinavir/sangre , Masculino , Persona de Mediana Edad , Combinación Trimetoprim y Sulfametoxazol/efectos adversos , Combinación Trimetoprim y Sulfametoxazol/sangreRESUMEN
A famotidine wafer that rapidly disperses on the tongue without water is a novel alternative to other histamine2 (H2)-antagonist dosage forms. Benefits associated with such a dosage form include convenience and potentially improved compliance for patients who dislike or have difficulty taking tablets and capsules. This report describes the research of three studies on the famotidine wafer dosage form. In the first trial, the bioequivalence and tolerability of the new 40-mg famotidine wafer and the marketed 40-mg famotidine tablet were studied in a 2-period crossover study (n = 18). The two formulations were bioequivalent as assessed by area under the plasma concentration versus time curve and maximum plasma concentration of famotidine. The plasma concentration of famotidine associated with 50% inhibition of pentagastrin stimulated gastric acid secretion (EC50; 10 ng/mL) was attained on average within 0.5 hours post-dose for the wafer and tablet. In a second trial, the tolerability of the famotidine 20-mg and 40-mg wafers or placebo given twice daily (bid) for 14 days were evaluated (n = 192). Both wafer strengths were well and equally tolerated. In a third trial of 450 subjects, the 40-mg wafer was preferred over tablets by 75% of the subjects, when they were asked to consider the method of administration and flavor. When used as an alternative to tablets and other conventional dosage forms, the wafers have the potential therapeutic benefit of improved compliance. It is concluded that similar systemic exposure, excellent tolerability, palatability, and preference make the famotidine wafer a clinically acceptable and convenient dosage from for patients on H2-antagonist therapy.
Asunto(s)
Sistemas de Liberación de Medicamentos , Famotidina/administración & dosificación , Administración Oral , Adulto , Anciano , Anciano de 80 o más Años , Estudios Cruzados , Tolerancia a Medicamentos , Femenino , Humanos , Masculino , Persona de Mediana Edad , Cooperación del Paciente , Método Simple Ciego , Equivalencia TerapéuticaRESUMEN
The effects of famotidine (80 mg per day), cimetidine (1600 mg per day), and placebo on theophylline pharmacokinetic parameters in chronic obstructive pulmonary disease (COPD) patients were compared. This was an open-label, randomized, three-period cross-over study, in which each subject first underwent a seven-day theophylline washout period, and thereafter received three single intravenous doses of theophylline (5 mg/kg infused over 30 minutes) during the study. Each of the experimental treatments was administered orally every 12 hours for a total of 9.5 days (19 doses). Theophylline was infused after the 17th dose of each treatment. Fourteen serial blood samples were collected before the start of each infusion, and for 30 hours after the end of each infusion. Plasma samples were assayed for theophylline, pharmacokinetic parameters were estimated, and treatment effects on each parameter were compared. Fourteen COPD patients completed all three periods of the investigation. Famotidine treatment had virtually no effect on any of theophylline's pharmacokinetic parameters. In contrast, cimetidine treatment significantly altered every pharmacokinetic parameter of theophylline as follows: Cimetidine decreased theophylline geometric mean CL from 2.74 L/h to 2.07 L/h (P < .001), and prolonged theophylline harmonic mean half-life from 6.6 to 9.6 hours (P < .001) and mean residence time from 10.8 to 15.0 hours (P < .001). Cimetidine treatment slightly increased theophylline volume of distribution by approximately 10%, and that change also was statistically significant (P = .032). The authors conclude that the treatment effects of cimetidine on theophylline pharmacokinetic parameters were in accord with those reported by others, and that famotidine treatment had no effect on any of theophylline's pharmacokinetic parameters in COPD patients.
Asunto(s)
Cimetidina/farmacología , Famotidina/farmacología , Enfermedades Pulmonares Obstructivas/metabolismo , Teofilina/farmacocinética , Adulto , Anciano , Estudios Cruzados , Interacciones Farmacológicas , Famotidina/uso terapéutico , Femenino , Humanos , Infusiones Intravenosas , Enfermedades Pulmonares Obstructivas/tratamiento farmacológico , Masculino , Persona de Mediana Edad , Teofilina/administración & dosificaciónRESUMEN
A rapid, sensitive and robust assay procedure using liquid chromatography coupled with tandem mass spectrometry (LC/MS/MS) for the determination of famotidine in human plasma and urine is described. Famotidine and the internal standard were isolated from plasma samples by cation-exchange solid-phase extraction with benzenesulfonic acid (SCX) cartridges. The urine assay used direct injection of a diluted urine sample. The chromatographic separation was accomplished by using a BDS Hypersil silica column with a mobile phase of acetonitrile-water containing trifluoroacetic acid. The MS/MS detection of the analytes was set in the positive ionization mode using electrospray ionization for sample introduction. The analyte and internal standard precursor-product ion combinations were monitored in the multiple-reaction monitoring mode. Assay calibration curves were linear in the concentration range 0.5--500 ng ml(-1) and 0.05--50 microg ml(-1) in plasma and urine, respectively. For the plasma assay, a 100 microl sample aliquot was subjected to extraction. To perform the urine assay, a 50 microl sample aliquot was used. The intra-day relative standard deviations at all concentration levels were <10%. The inter-day consistency was assessed by running quality control samples during each daily run. The limit of quantification was 0.5 ng ml(-1) in plasma and 0.05 microg ml(-1) in urine. The methods were utilized to support clinical pharmacokinetic studies in infants aged 0-12 months.
Asunto(s)
Cromatografía Líquida de Alta Presión/métodos , Famotidina/sangre , Antagonistas de los Receptores H2 de la Histamina/sangre , Espectrometría de Masas/métodos , Famotidina/farmacocinética , Famotidina/orina , Antagonistas de los Receptores H2 de la Histamina/farmacocinética , Antagonistas de los Receptores H2 de la Histamina/orina , Humanos , Indicadores y Reactivos , Lactante , Recién Nacido , Control de Calidad , Sensibilidad y Especificidad , Ácido TrifluoroacéticoRESUMEN
The gastrointestinal transit and systemic absorption of Sinemet CR (50-200) controlled-release tablets and standard Sinemet (25-100) immediate-release (IR) tablets have been studied in fasted and fed healthy human subjects. Both formulations were labelled with a gamma-emitting radionuclide and their gastric emptying, colon arrival and in vivo disintegration profiles monitored using gamma scintigraphy. The IR dosage forms were found to disperse soon after administration and to empty rapidly from both fasted and fed stomachs. Erosion of the CR system was independent of food or stomach pH. The CR tablet was observed to disintegrate fully in the gastrointestinal (GI) tract, resulting in complete release of levodopa over a 3-4 h time period. Considerable intersubject variation was found to exist for levodopa absorption. Absorption was more protracted with Sinemet CR than with standard Sinemet, due to the controlled release characteristics of the tablet matrix. There was no rapid initial absorption phase and instead, a gradual build-up in the absorption profile occurred.
Asunto(s)
Antiparkinsonianos/farmacocinética , Carbidopa/farmacocinética , Tránsito Gastrointestinal/efectos de los fármacos , Levodopa/farmacocinética , Adulto , Antiparkinsonianos/farmacología , Carbidopa/farmacología , Preparaciones de Acción Retardada , Combinación de Medicamentos , Alimentos , Tránsito Gastrointestinal/fisiología , Humanos , Concentración de Iones de Hidrógeno , Absorción Intestinal/efectos de los fármacos , Levodopa/farmacología , Masculino , Valores de Referencia , Estómago/efectos de los fármacos , Estómago/fisiologíaRESUMEN
A new method is presented for the determination of kinetic parameters based on a functional relationship among experimental data derived from the postulated model. The data, even though containing errors, are manifestations of this relationship, which should be satisfied by parameters fitted to the system. The procedure involves the use of numerical integration and/or differentiation of the data, followed by multiple linear regression. It does not require initial estimates or repetitive iteration for linear systems and can be applied to nonlinear models. The accuracy of estimated parameter depends on the goodness of the particular numerical approximation method used.
Asunto(s)
Cinética , Computadores , Matemática , Modelos Teóricos , Análisis de RegresiónRESUMEN
The distribution of a homologous series of p-alkylpyridines between water and six organic solvents with varying degrees of polarity was investigated. The distribution coefficients were considered as reflections of the strength of net interactions involved in the solvents. The order was chloroform greater than octanol greater than carbon tetrachloride greater than butyl ether greater than hexadecane greater than octane. The effect of the methylene group upon the distribution coefficients differed little among the six solvents. The relative constancy was attributed to the predominance of the dispersion forces in the incremental effect.
Asunto(s)
Piridinas , Concentración de Iones de Hidrógeno , Aceites , Picolinas , Solubilidad , Relación Estructura-Actividad , AguaRESUMEN
The hypothetical hexadecane-octane distribution coefficients for the alkylpyridines were deduced from the corresponding oil-water distribution data. The values were analyzed by a modified regular solution theory. A good correlation was noted by including the Flory-Huggins entropy factor in the calculation and by considering the deviation from the geometric mean assumption.
Asunto(s)
Piridinas , Fenómenos Químicos , Química , Hidrocarburos , Aceites , Picolinas , Solubilidad , AguaRESUMEN
The flexibility of bioavailability assessment at quasi-and nonsteady state is demonstrated by systematically removing experimental constraints from the study design. Mathematical expressions are derived to describe each design variation. From the resultant solutions, it is evident that the proposed method can accommodate nonuniformities in dose, dosage interval, dosage regimen, dosing cycle, sampling interval, plasma half-life, washout period, and protocol adherence. Nominal requirements for the method are linear kinetics and mean plasma concentrations estimated over time intervals beginning and ending in the log-linear region.
Asunto(s)
Disponibilidad Biológica , Biofarmacia , Semivida , Cinética , Modelos Biológicos , Preparaciones Farmacéuticas/administración & dosificaciónRESUMEN
Two numerical examples are presented to illustrate the application of the proposed method of parameter estimation in pharmacokinetics. Results for a system exemplifying first-order kinetics indicate that parameters estimated by the proposed procedure compare favorably with those estimated by a nonlinear regression method. In a simulated example characterized by Michaelis-Menten elimination kinetics, the accuracy of the estimated parameters was comparable to that expected, verifying the validity of the method. The importance of the numerical approximation algorithms was demonstrated also.